HOME >> BIOLOGY >> NEWS
New study indicates arsenic could be suitable as first-line treatment in type of leukaemia

Geneva, Switzerland: Arsenic trioxide a highly poisonous substance best known as an effective weed killer or pesticide and notorious for being a favourite 'weapon' of choice in murder mystery novels, is being re-invented as a treatment for a rare type of leukaemia.

It is already licensed as an orphan drug (the term for drugs intended to treat rare conditions) for patients who have relapsed after initial therapy for acute promyeloctytic leukaemia (APL).

But now, a research team led by Dr. Ardeshir Ghavamzadeh and Dr. Kamran Alimoghaddam at Tehran University of Medical Sciences in Iran, are running a trial of its use in newly diagnosed APL patients who have received no prior therapy, and they are impressed enough with its effectiveness to suggest that it should now be considered as a first-line treatment for APL. They also believe it is likely to prove effective in other cancers such as multiple myeloma.

Dr. Ghavamzadeh, professor of medicine at Tehran University, today (Wednesday 29 September) reported at the EORTC-NCI-AACR[1] Symposium on Molecular Targets and Cancer Therapeutics in Geneva that two courses of the drug achieved complete remission in over 90% of the 63 patients in a Phase II study being carried out at the city's Hematology, Oncology and Bone Marrow Transplant Center. 88.5% of patients were still alive with a mean survival time to date of nearly 34 months. Of 11 patients who relapsed, eight went back into remission after a third cycle of treatment. Six patients in the trial have died.

APL accounts for around 10% of acute myeloid leukaemias and affects an estimated 20,000 people worldwide each year. It is a cancer of the white blood cells, characterized by a rapid accumulation of abnormal white cells in the bone marrow and the blood, resulting in anaemia, bleeding and susceptibility to infections. It occurs in people of all ages, although it is more common in older people. The five-year survival rate for patients receiv
'"/>

Contact: Margaret Willson
m.willson@mwcommunications.org.uk
41-227-612-205
European Organisation for Research and Treatment of Cancer
29-Sep-2004


Page: 1 2 3

Related biology news :

1. Student science contest participation influences study, career choices, alumni say
2. New study shows hope for treating inhalant abuse
3. International study findings link acne-like rash to effectiveness of new targeted cancer treatment
4. Cigarette smoke causes breaks in DNA and defects to a cells chromosomes, Pitt study finds
5. Phase II trials of second-generation antisense cancer drug planned following successful early study
6. Preclinical safety study shows adipose-derived stem cells improve heart function after heart attack
7. Indiana University, EPA to study airborne PCBs
8. K-State, other universities to study how climate affects plant evolution
9. USC study links historical increases in life span to lower childhood exposure to infection
10. Washington University in St. Louis leads group studying aging process
11. Simian virus 40 not associated with non-Hodgkin lymphoma, study shows

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/20/2019)... ... January 16, 2019 , ... uBiome, the leader in microbial ... uses artificial intelligence (AI) and a data-centric approach to decentralize medicine using blockchain ... , People will Crohn’s or other chronic medical conditions join a relevant study ...
(Date:1/14/2019)... ... January 14, 2019 , ... CellMax Life , a ... blood, will present new findings at the ASCO Gastrointestinal Cancer Symposium in San ... results from this study show CellMax Life’s blood test, based on its proprietary ...
(Date:1/10/2019)... , ... January 10, 2019 , ... ... the translational gap between inexpensive in vitro studies and significantly more expensive in ... in vivo efficacy and toxicity. To address this need, researchers have begun to ...
Breaking Biology News(10 mins):
(Date:2/12/2019)... SAN FRANCISCO (PRWEB) , ... February 12, 2019 ... ... (CRO) specializing in dermatology, has finalized a deal to extend their use of ... diagnostics clinical trials, through 2023. The CRO has been a regular Medrio customer ...
(Date:2/2/2019)... ... February 01, 2019 , ... Biomatlante, a ... of its new CEO, Julien Dert, being effective on February 1st, 2019. , ... finance and management, in which more than 12 years in the Medical Device ...
(Date:1/30/2019)... ... January 29, 2019 , ... K&R Negotiations announced today that Mladen ... special online event titled: Six Ways to Shorten the Sales Cycle : Reduce ... 2019 on the BrightTALK network. , Negotiation expert Kresic will discuss the realities ...
(Date:1/28/2019)... ... January 28, 2019 , ... ... low molecular weight compounds. In this early stage, false positives can be problematic ... time, it is vital that screening techniques are highly sensitive to detect weak ...
Breaking Biology Technology:
Cached News: